Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human
immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market …

A substantial number of studies have been performed across the world to determine
transmitted drug resistance. Large variations between different parts of the world can be …

Objective. The objective of this study was to systematically characterize the incidence and
determinants of antiretroviral resistance in the HOMER (Highly Active Antiretroviral Therapy …

Background Treatment options for HIV-1 infected individuals who have received extensive
previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non …

Background A single intrapartum dose of nevirapine for the prevention of mother-to-child
transmission of human immunodeficiency virus (HIV) leads to the selection of resistance …

This study examined the relationship between ex vivo human immunodeficiency virus type 1
(HIV-1) fitness and viral genetic diversity during the course of HIV-1 disease. Primary HIV-1 …

To address drug resistance to HIV-1 non-nucleoside reverse transcriptase inhibitors
(NNRTIs), a series of novel diarylpyrimidine (DAPY) derivatives targeting “tolerant region I” …

Doravirine (DOR, formerly known as MK-1439) is a human immunodeficiency type 1 virus
(HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) that is currently in phase 2b …

This work follows on from our initial discovery of a series of piperidine-substituted thiophene
[3, 2-d] pyrimidine HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI)(J. Med …

Objective: To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278,
a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or …